Abivax S.A.
OTC: AAVXF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Marc de Garidel
- Employees
- 69
- Headquarters
- Paris, France
- IPO year
- 2016
- Market cap
- $6.4B
- Website
- https://www.abivax.com
Loading AAVXF…
Loading profile data…Frequently asked questions about AAVXF
What does Abivax S.A. (AAVXF) do?
Abivax S.A., a French biopharmaceutical firm, specializes in the discovery and enhancement of pharmaceutical treatments targeting inflammatory conditions, infectious illnesses, and various forms of cancer. The company's flagship compound, ABX464, is currently undergoing Phase IIb clinical evaluations for ulcerative colitis, Crohn's disease, and...
Where does AAVXF trade?
Abivax S.A. (AAVXF) trades on the Other OTC.
What sector is AAVXF in?
Abivax S.A. (AAVXF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Abivax S.A.?
Marc de Garidel is the chief executive officer of Abivax S.A. (AAVXF).
Where is Abivax S.A. headquartered?
Abivax S.A. is headquartered in France.
Does AAVXF pay a dividend?
Abivax S.A. (AAVXF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AAVXF go public?
Abivax S.A. (AAVXF) completed its initial public offering in 2016.